News >

Further Evidence Needed Supporting Clinical Utility of Liquid Biopsies in GI Cancers

Kristi Rosa
Published: Monday, Feb 04, 2019

John Strickler, MD

John Strickler, MD
Liquid biopsies offer a potential precision medicine approach in patients with gastrointestinal (GI) cancers, as they provide clinicians with information to guide treatment decisions in a minimally invasive way. However, more data are needed to support the clinical utility of these assays, said John Strickler, MD.

“Currently there are commercially available cell-free DNA (cfDNA) assays, which we can use in the clinic and we know that those assays have analytical and clinical validity,” said Strickler, assistant professor of medicine, Duke Cancer Institute. “We order them in select circumstances. But in terms of showing clinical utility—that’s still a work in progress.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x